Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04DNL
|
|||
| Former ID |
DIB015308
|
|||
| Drug Name |
ALN-FLU01
|
|||
| Synonyms |
RNAi therapeutic (influenza), Alnylam/Novartis; NP/NA gene-silencing siRNA (influenza infection), Alnylam/Novartis
Click to Show/Hide
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Influenza virus infection [ICD-11: 1E30-1E32] | Preclinical | [1] | |
| Company |
Alnylam Pharmaceuticals Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Influenza NA messenger RNA (Influenza NA mRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022658) | |||
| REF 2 | Respiratory viral diseases: access to RNA interference therapy. Drug Discov Today Ther Strateg. 2007; 4(4): 273-276. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.